Health MindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial May 17, 2021
Health MindMed Signs Partnership with Swiss Psychedelic Drug Discovery Startup MindShift Compounds AG, Expands Development Pipeline and IP Portfolio with Next-Gen Psychedelic and Empathogenic Compounds February 11, 2021
Health Leading Psychedelic Pharmaceutical Company MindMed Forms New Board Committee To Evaluate Acquisitions And Scientific Collaborations March 12, 2020
Search
